“News neutrality by unbiased coverage”
One News Page
> >

Biofrontera AG:

EQS Group Monday, 15 October 2018
DGAP-News: Biofrontera AG / Key word(s): Conference

15.10.2018 / 09:48
The issuer is solely responsible for the content of this announcement.

*Biofrontera to Present at the 4^th Annual Dawson James Small Cap Growth Stock Conference*

*Leverkusen, Germany, October 15, 2018* - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann Lübbert, Biofrontera's Chief Executive Officer, is scheduled to present at the 4^th Annual Dawson James Small Cap Growth Stock Conference, being held on October 29-30, 2018 at Wyndham Grand Hotel in Jupiter, FL.

Details of the presentation are below:

*Event:* 4^th Annual Dawson James Small Cap Growth Stock Conference

*Date:* Tuesday, October 30, 2018

*Time:* 11:00am ET

*Location:* Track 1 - Preserve Ballroom C

Biofrontera's management team will also be available for one-on-one meetings with investors who are registered to attend the event. Alternatively, interested investors may contact Tram Bui of The Ruth Group at or (646) 536-7035 to schedule a meeting.


*Enquiries, please contact:

Biofrontera AG *
Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0

*IR UK: Seton Services *
Toni Vallen

+44(0) 20 7729 0805

*IR and PR US: The Ruth Group*
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

*About Biofrontera:*

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at

*Forward Looking Statements:*

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.


15.10.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at --------------------

Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service

Recent related news from verified sources

Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Nov. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings...
GlobeNewswire - Press Releases

Biofrontera AG: Biofrontera reports earnings results for the third quarter and first nine months of 2018

DGAP-News: Biofrontera AG / Key word(s): 9-month figures 16.11.2018 / 08:05 The issuer is solely responsible for the content of this announcement. ...
EQS Group - Press ReleasesAlso reported by •GlobeNewswireSeekingAlpha

Biofrontera 9M revenues up 100%

SeekingAlpha - Markets

You Might Like

Tweets about this

Other recent news in Press Releases

Manufacturing INDONESIA 2018: Bringing Technologies to Drive Industry 4.0 for Successful EconomyOmaha Steaks Announces BLACK FRIDAY and Cyber Monday Specials in-Store and Online
AMERICAN National Bankshares Inc. Announces Fourth Quarter 2018 DividendNew Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse FINANCE, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest